stockrowAdaptive Biotechnologies Corporation
ADPT Healthcare Diagnostics & Research
Adaptive Biotechnologies Corporation’s revenue for fiscal 2025 (year ended December 2025) was $277.0 million, up 54.8% from fiscal 2024.
- Revenue
- −10.7%
- EPS
- −66.7%
- Free cash flow
- +201.9%
Quarter to September 2026, against a year earlier
Follow ADPT
Alert me
Adaptive Biotechnologies Corporation (ADPT) Current ratio
Adaptive Biotechnologies Corporation's current ratio at the end of the quarter to 30 September 2026 was 4.0×, up 0.6× from fiscal 2025 (3.3×). Over the past ten years it has ranged from 2.9× (fiscal 2024) to 9.8× (fiscal 2017); the current reading is higher than 22% of that period. That is above the Diagnostics & Research industry median of 2.3× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 3.3× | 15.36% |
| FY2024 | 2.9× | (37.90%) |
| FY2023 | 4.7× | (8.98%) |
| FY2022 | 5.1× | 44.69% |
| FY2021 | 3.5× | (48.79%) |
| FY2020 | 6.9× | (11.68%) |
| FY2019 | 7.8× | (1.29%) |
| FY2018 | 7.9× | (18.89%) |
| FY2017 | 9.8× | — |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 4.0× | (17.25%) |
| Jun 2026 | 4.8× | 42.97% |
| Mar 2026 | 3.4× | 0.46% |
| Dec 2025 | 3.3× | (1.11%) |
| 28 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| BLLN BillionToOne, Inc. compare | 11.2× |
| GRAL GRAIL, Inc. compare | 8.9× |
| VCYT Veracyte, Inc. compare | 5.6× |
| ADPT Adaptive Biotechnologies Corporation | 4.0× |
| NEO NeoGenomics, Inc. compare | 3.5× |
| WGS GeneDx Holdings Corp. compare | 3.3× |
| SHC Sotera Health Company compare | 3.1× |
| CDNA CareDx, Inc. compare | 2.3× |
| RDNT RadNet, Inc. compare | 1.5× |
| Diagnostics & Research industry median | 2.3× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on ADPT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement